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INTRODUCTION
Dementia is a neurodegenerative disease of the brain, result-
ing in impairment of mental abilities. Many cases of demen-
tia, including Alzheimer’s disease (AD), are characterized by 
denervation of cholinergic neurons in the hippocampus and 
entorhinal cortex and subsequent memory impairment.1 While 
the exact pathophysiology of dementia is still under active de-
bate, studies have shown reduction in choline acetyltransfer-
ase (ChAT) activity in the hippocampus and frontal cortex of 
dementia patients.2 Additionally, lesions of basal forebrain cho-
linergic neurons in rats induced by the injection of 192 IgG-
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Purpose: Loss of cholinergic neurons in the hippocampus is a hallmark of many dementias. Administration of stem cells as a 
therapeutic intervention for patients is under active investigation, but the optimal stem cell type and transplantation modality 
has not yet been established. In this study, we studied the therapeutic effects of human placenta-derived mesenchymal stem cells 
(pMSCs) in dementia rat model using either intracerebroventricular (ICV) or intravenous (IV) injections and analyzed their 
mechanisms of therapeutic action.
Materials and Methods: Dementia modeling was established by intraventricular injection of 192 IgG-saporin, which causes le-
sion of cholinergic neurons. Sixty-five male Sprague-Dawley rats were divided into five groups: control, lesion, lesion+ICV injec-
tion of pMSCs, lesion+IV injection of pMSCs, and lesion+donepezil. Rats were subjected to the Morris water maze and subse-
quent immunostaining analyses.
Results: Both ICV and IV pMSC administrations allowed significant cognitive recovery compared to the lesioned rats. Acetylcho-
linesterase activity was significantly rescued in the hippocampus of rats injected with pMSCs post-lesion. Choline acetyltransfer-
ase did not co-localize with pMSCs, showing that pMSCs did not directly differentiate into cholinergic cells. Number of microglial 
cells increased in lesioned rats and significantly decreased back to normal levels with pMSC injection. 
Conclusion: Our results suggest that ICV and IV injections of pMSCs facilitate the recovery of cholinergic neuronal populations 
and cognitive behavior. This recovery likely occurs through paracrine effects that resemble microglia function rather than direct 
differentiation of injected pMSCs into cholinergic neurons.
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saporin, an immunotoxin, leads to cholinergic hypofunction 
and eventually results in considerable impairment of cognitive 
function and behavior.3 Thus, various previous studies have uti-
lized 192 IgG-saporin administrations as a method of neuro-
degenerative dementia rat model establishment.4-6
Acetylcholinesterase (AChE) inhibitors are an FDA-approved 
drug for dementia patients, but this method has shown limited 
efficacy, calling for a more effective treatment method. Alter-
natively, mesenchymal stem cells (MSCs) have been actively 
researched for their therapeutic potential against neurode-
generative disorders,7 and MSCs were found to secrete neuro-
regulatory factors that carry out neuroprotective actions and 
promote neurogenesis.8 Some studies using MSC have report-
ed promising results for neurodegenerative disease models. 
In 6-hydroxydopamine-induced Parkinson’s disease (PD) rat 
models, intravenous administration of human bone marrow-
derived MSCs was found to alleviate explicit parkinsonian 
symptoms, suggesting that MSC administration could elicit 
therapeutic effects on neurodegenerative diseases pertaining 
to dopaminergic neurons.9 Also, human adipose tissue-derived 
MSCs (ADSCs) facilitated β-amyloid peptide (Aβ) clearance 
via in vitro secretion of exosomes containing the Aβ-degrading 
enzyme neprilysin, suggesting a possible therapeutic approach 
to AD using ADSCs.10
While MSC administration for therapeutic intervention of 
neurodegenerative disorders is rising in popularity, limited 
information is available regarding the most appropriate source 
of MSCs for transplantation. Human placenta-derived MSCs 
(pMSCs) exhibit high adhesive and secretory properties.11 
Moreover, procurement of pMSCs does not conflict with ethical 
concerns12 and they display phenotypic plasticity.13 They are 
also immunologically privileged14 and are easily obtainable 
without invasive procedures. Based on such advantages, pM-
SCs seem to be a viable candidate for transplantation in neu-
rodegenerative dementia models.
MSC transplantation was shown to influence microglia ac-
tivation in AD mouse models and reduce Aβ deposition.15 Mi-
croglia are glial cells that defend the neural parenchyma from 
factors such as infections, ischemia, and neurodegeneration.15 
Microglial cells are known to help maintain neural stem cell 
homeostasis and participate in immunological actions through 
phagocytic activity.16 In addition, microglia have been shown 
to serve neuroprotective functions through secretion of various 
factors and increasing neuronal survival,17 and microglia in the 
hippocampus of stroke rat models were shown to protect neu-
rons by synthesizing tumor necrosis factors.18 Thus, we antici-
pated that active microglia quantity would grow in dementia 
model rats with lesions of cholinergic neurons and decrease 
upon appropriate treatments that allow recovery in cholinergic 
function.
As mentioned above, there have been studies showing that 
stem cell administration alleviates symptoms in PD and AD 
models. However, to our knowledge, the therapeutic effect of 
pMSCs in dementia models with cholinergic neuronal degen-
eration and its associated mechanisms are less understood. In 
this study, we evaluated the behavioral recovery effects of pMSC 
administration in 192 IgG-saporin-induced dementia model 
rats in comparison with the current standard treatment using 
donepezil, an AChE inhibitor. 
Furthermore, we investigated the therapeutic effects of ad-
ministration of pMSCs in dementia model rats using two dif-
ferent cell injection methods, intracerebroventricular (ICV) and 
intravenous (IV) injections, and also the possible mechanisms 
of therapeutic action. Hemodynamic considerations may sug-
gest better stem cell delivery through intra-arterial (IA) injec-
tions, however, our previous IA injection trials entailed several 
difficulties: considerable invasiveness involving incision through 
neck skin and muscles, uncontrollable bleeding, and extend-
ed recovery time post-operation. Thus, as the two prime injec-
tion methods of our study, we selected the ICV route, which is 
invasive but highly target-specific, and the IV route, which al-
lows marginal invasiveness and faster stem cell administration. 
MATERIALS AND METHODS
Animals and experimental grouping
All animal experiments in this study were performed in accor-
dance with the Guide for the Care and Use of Laboratory Ani-
mals of the National Institutes of Health and were approved 
by the Institutional Animal Care and Use Committee of Yonsei 
University, Korea. 
Procedures were carried out according to the experiment 
timeline (Fig. 1). Rats were housed in groups of three per cage 
with food and water ad libitum, and they were kept in a tem-
perature/humidity-controlled room with a 12-hour light/12-
hour dark cycle. Efforts were taken to minimize the number of 
rats used and overall animal suffering.
Fig. 1. Experiment timeline. pMSC, placenta-derived mesenchymal stem cell. 
pMSC transplant
(2 weeks)
Probe test/sampling
(8 weeks)
Water maze
(7 weeks)
Modeling
(1 week)
Rat arrival
(0 weeks)
Daily donepezil injection
Immunosuppression (daily cyclosporine injection)
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Experimental grouping is summarized in Table 1. Sixty-five 
male Sprague-Dawley rats (180−200 g) were randomly assort-
ed into five groups before surgery. The control group rats (n= 
16) did not undergo any surgical procedures. The lesion group 
rats (n=17) received bilateral ventricular infusion of 192 IgG-
saporin into the brain. Rats in the ICV transplantation group 
(n=12) were bilaterally infused with 192 IgG-saporin in the 
lateral ventricle and received ICV injection of pMSCs one week 
later. Rats in the IV transplantation group (n=12) were bilater-
ally infused with 192 IgG-saporin in the lateral ventricle and 
received tail vein injection of pMSCs one week afterwards. 
Lastly, rats in the donepezil group (n=8) were bilaterally in-
fused with 192 IgG-saporin in the lateral ventricle and were in-
traperitoneally injected with donepezil every day after pMSC 
transplantation in the ICV and IV group rats.
Surgical procedures
Forty-nine rats (excluding the control group) were anesthetized 
with a mixture of ketamine (75 mg/kg), xylazine (RompunTM 4 
mg/kg; Bayer Korea, Seoul, Korea), and acepromazine (0.75 
mg/kg) and were secured in a stereotaxic frame. Scalp skin was 
incised, and two holes were drilled into the skull [anteroposte-
rior (AP) -0.8 mm, mediolateral (ML) ±1.2 mm, dorsoventricular 
(DV) -3.4 mm]. Afterwards, 8 μL of 192 IgG-saporin (0.63 μg/μL; 
Chemicon, Temecula, CA, USA) were bilaterally injected into 
the lateral ventricle at a rate of 1 μL/min and was left to diffuse 
for 5 min after injection. 
pMSCs were harvested and isolated from normal human pla-
centa according to protocols described in previous studies.19 
MSC harvestation procedure on human donors was approved 
by the Institutional Review Board of CHA General Hospital, 
Seoul, Korea. Cell surface marker profiling in our previous stud-
ies also revealed that the pMSCs were negative for CD34 (a 
hematopoietic and endothelial cell marker), SSEA4, TRA-1-60, 
and TRA-1-81 (embryonic stem cell markers), and positive for 
CD9 (a nontrophoblast marker), CD13 and CD90 (MSC mark-
ers), and CD200 (an immunoregulator).19 One week after 192 
IgG-saporin injections, 12 rats in the ICV group were anesthe-
tized with a mixture of ketamine, xylazine, and acepromazine. 
Afterwards, the rats received 6 μL of pMSC (9×105 cells/6 μL, 3 
μL/5 min) transplantation into the following coordinates: AP 
-0.8 mm, ML ±1.2 mm, DV -3.4 mm. The pMSCs were allowed 
to diffuse for 5 min after each injection. Twelve rats in the IV 
group received 200 μL of pMSCs (5×106 cells/200 μL) via tail 
vein injection. All rats were immunosuppressed with cyclo-
sporine [12.5 mg/kg, daily intraperitoneal (IP) injection] start-
ing the day before transplantation for up to five weeks. Eight 
rats were used for the donepezil injection group (3 mg/kg, 
daily IP injection). 
Additionally, in order to exclude the possible effects of sur-
gical procedures on microglial cell count, four rats were sham-
operated [bilateral injection of 8 μL phosphate buffer saline 
(PBS)], and their microglial cell counts were compared with 
those of control group rats.
Behavioral test–Morris water maze
Five weeks after pMSC transplantation, all rats underwent the 
Morris water maze test. The Morris water maze apparatus was 
made up of a circular pool 2 m in diameter and 0.5 m in depth. 
This pool was filled with opaque tap water (23°C) and con-
cealed a circular (0.15 m in diameter) black escape platform 
submerged 2 cm below the surface of the water. All rats were 
trained for four trials per day. These four trials continued for 5 
consecutive days with a fixed hidden platform guided by spatial 
cues. For each training trial, the rat was semi-randomly placed 
into one of the four start points and was given 60 sec to reach 
the hidden platform. After finding the platform, the rat was al-
lowed to remain on the platform for 10 sec. Rats that failed to 
reach the platform within 60 sec were led to the platform by 
the experimenter and were allowed to remain on the platform 
for 10 sec. Twenty-four hours after the final training trial, the 
rats were given probe tests. Each probe test lasted for 60 sec 
without the platform. Swimming distance, time spent in each 
zone, swim path, and speed were recorded and computed by 
the SMART video-tracking system (Harvard Apparatus, Hol-
liston, MA, USA).
Tissue preparation
After the behavioral tests, 8 out of 16 rats from the control group, 
8 out of 17 rats from the lesion group, 6 out of 12 rats from the 
ICV group, 6 out of 12 rats from the IV group, and 4 out of 8 rats 
from the donepezil injection group were anesthetized with a 
mixture of ketamine (75 mg/kg), xylazine (4 mg/kg), and 
acepromazine (0.75 mg/kg) and underwent transcardial per-
fusion with normal saline and cold 4% paraformaldehyde. 
Brains were removed, post-fixed, transferred to 30% sucrose, 
Table 1. Grouping of Experimental Subjects
Groups n 192 IgG-saporin pMSC Donepezil
Control 16 - - -
Lesion 17 ICV, bilateral - -
ICV 12 ICV, bilateral ICV, bilateral -
IV 12 ICV, bilateral IV -
Donepezil   8 ICV, bilateral - IP
pMSC, placenta-derived mesenchymal stem cell; ICV, intracerebroventricular; IV, intravenous; IP, intraperitoneal.
“-” indicates no injection.
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and stored for 3 days. The brains were sectioned into 35 μm 
slices using a freezing microtome and stored in a cryoprotec-
tant solution [0.1 M phosphate buffer (pH 7.2), 30% sucrose, 
1% polyvinylpyrrolidone, and 30% ethylene glycol] at -20°C.
AChE assay
The remaining rats from each group were anesthetized with a 
mixture of ketamine (75 mg/kg), xylazine (4 mg/kg), and ace-
promazine (0.75 mg/kg) and then decapitated with a guillotine. 
The brains were quickly removed. The prefrontal cortex, hip-
pocampus, and medial septum (MS) regions were dissected 
with fine forceps from 1 mm coronal brain slices. These sam-
ples were homogenized in lysis buffer (Intron, Seongnam, 
Korea) and centrifuged for 10 min at 12000 rpm. The protein in 
the supernatant was measured using the bicinchoninic acid 
protein assay reagent kit (Pierce, Rockford, IL, USA). The pro-
tein samples were stored at -70°C.
To evaluate the enzymatic activity of AChE, the method de-
scribed by Ellman, et al.20 was used. In brief, 20 µL triplicate 
samples were mixed with a reaction mixture [0.2 mM dithio-
bisnitrobenzoic acid (Sigma-Aldrich, Louis, MO, USA), 0.56 mM 
acetylthiocholine iodide (Sigma-Aldrich), 10 µM tetraisopro-
pyl pyrophosphoramide (Sigma-Aldrich), and 39 mM phos-
phate buffer; pH 7.2] at 37°C. After 30 min, the optical density 
was measured at 405 nm.
Immunohistochemistry
DAB staining
Diaminobenzidine (DAB) staining was performed to evaluate 
the location and number of pMSCs. For immunohistochemis-
try, brain sections were incubated in 0.3% H2O2 for 60 min to 
block endogenous peroxidase activity. The sections were bl-
ocked with 5% normal goat serum and incubated overnight 
with monoclonal antibodies against a human cytoplasmic pro-
tein (STEM121, AB-121-U-050, 1:300; StemCells, Cambridge, 
UK) at 4°C. Afterwards, the sections were incubated with anti-
mouse biotinylated IgG secondary antibodies (BA-9200; Vec-
tor Laboratories, Burlingame, CA, USA), followed by the avi-
din-biotin complex method (ABC Elite; Vector Laboratories). 
The cells were then visualized using a DAB substrate kit (Ther-
mo, Fremont, CA, USA). The samples were examined using a 
virtual microscope (BX51; Olympus, Tokyo, Japan).
ChAT and microglia immunofluorescence analysis
For immunofluorescence analysis of ChAT, sections were in-
cubated overnight at 4°C with monoclonal antibodies against 
human nuclei (MAB1281; Merck Millipore, Billerica, MA, 
USA) and ChAT (Anti-ChAT, 1:100; Merck Millipore). The sec-
tions were then incubated with anti-mouse Cy5 (A10524, 
1:500; Life Technologies, Carlsbad, CA, USA) and anti-goat 
FITC (Ab6881, 1:200; Santa Cruz Biotechnology, Dallas, TX, 
USA). For immunofluorescence analysis of microglial cells, 
sections were incubated overnight at 4°C with monoclonal 
antibodies against microglia (Iba1, 019-19741, 1:400; Wako 
Chemicals, Richmond, VA, USA). The sections were subse-
quently incubated with anti-rabbit Alexa Fluor 488 (A11008, 
1:500; Invitrogen, Carlsbad, CA, USA) secondary antibodies. The 
samples were examined and photographed with a confocal 
laser scanning microscope (LSM700; Carl Zeiss, Jena, Germany).
Statistical analysis
Statistical analyses were conducted using SPSS software ver. 
21 (IBM Corp., Armonk, NY, USA). All analyses were performed 
using one-way analysis of variance (ANOVA) followed by post 
hoc Fisher’s least significant difference method for exploratory 
analysis of our factors. Data are presented as mean±standard 
error. p-value <0.05 was considered statistically significant.
RESULTS
Morris water maze test
Prior to probe testing, all rats were trained in the water maze 
for four trials per day for five consecutive days. On average, rats 
in all five groups showed a gradual decline in latency to the 
platform over the five days (Fig. 2A). Twenty-four hours after 
the final training trial, the rats were subjected to probe testing. 
Three measurements were made in the probe trial: time spent 
in the target quadrant, time spent in the platform zone, and the 
number of platform zone crossings.
In the probe test, the lesion group rats showed poor perfor-
mance compared to the control rats in all three measurements 
of interest (Fig. 2B, C, and D). ICV and IV group rats all showed 
significant improvement in all three measurements compared 
to the lesioned rats (Fig. 2B, C, and D). Donepezil group rats 
also showed significant improvement in time spent in the tar-
get quadrant and in the platform area but did not show a signif-
icant difference from the lesion group in the number of plat-
form crossings (Fig. 2B, C, and D).
Cholinergic functions
In order to compare cholinergic neuronal activity, we quanti-
fied AChE activity in all groups using Ellman’s methods.20 This 
measurement was made in three parts of the rats’ brains: the 
medial prefrontal cortex (mPFC), the hippocampus, and the 
MS. In the mPFC and hippocampal regions, AChE activity was 
significantly reduced in the lesion group compared to the con-
trol group (Fig. 3A and B). AChE activity in the MS also declined 
in the lesion group, although the difference from controls was 
not statistically significant (Fig. 3C). In the mPFC and hippo-
campus, AChE activities of ICV and IV group rats significantly 
improved compared to that of the lesioned rats, suggesting that 
pMSC administration boosts cholinergic neuronal function to 
a level similar to rats without dementia (Fig. 3A and B). In con-
trast, lesion, ICV, IV, and donepezil group rats all tended to show 
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lower levels of AChE activity in the MS region compared to con-
trol rats, but the difference was not significant (Fig. 3C). Over-
all, ICV and IV pMSC administrations showed therapeutic ef-
fects similar to that of donepezil.
Localization of pMSCs
Placental MSC homing was investigated for ICV and IV groups 
to evaluate the effectiveness of the injection methods. The in-
jected pMSCs were counted after DAB staining for STEM121, 
and indeed certain portions of pMSCs were found for both 
methods (ICV 2727.5±574.332 cells; IV 7172.5±1041.075 cells) 
at the dentate gyrus of the hippocampal region (Fig. 4). Per-
centages of localized pMSCs at the dentate gyrus with respect 
to the total number of injected cells were approximately 0.30% 
in the ICV group and 0.14% in the IV group.
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Stem cell fate
To take into account the possibility of differentiation of the in-
jected stem cells into cholinergic neurons, rat brain sections 
from all groups were subjected to immunofluorescence anal-
ysis using markers for human nuclei and for ChAT. Many stem 
cells were found in the hippocampus, but we could not detect 
any co-localizations between the stem cell nuclei marker and 
the ChAT marker (Fig. 5). The injected stem cells did not seem 
to differentiate into cholinergic neurons.
Microglial activity
Microglial cell count was carried out for control, lesion, ICV, 
and IV group rats using the microglial cell marker, Iba1. The 
cell count was performed for the dentate gyrus region. In or-
der to exclude the possibility of any influences on microglial 
cell count invoked by the operation procedures, numbers of 
microglial cells were compared across the four groups togeth-
er with a fifth sham-operated group. One-way ANOVA results 
showed similar trends in microglial cell count for the control 
and the sham-operated groups: both groups showed a signifi-
cant difference from the lesion group, whereas both groups 
showed no significant difference from either ICV or IV groups 
(significance level of 0.05 for all pairwise comparisons). The 
normal and sham-operated groups did not show a significant 
difference from each other. For consistency, data for sham-
operated group rats were not included in the figure. The num-
ber of microglial cells markedly increased; the control group 
(326.7±22.11 cells) and the lesion group (541.4±19.55 cells). 
Both ICV and IV administration of pMSCs led to a significant 
decrease of microglia count compared to the lesion group 
(ICV 382.6±10.43 cells; IV 282.8±11.35 cells) (Fig. 6). Both ICV 
and IV groups showed no significant difference from the con-
trol group in microglial cell count.
DISCUSSION
Dementia caused by cholinergic neuronal degeneration is 
currently treated with AChE inhibitors such as donepezil, but 
these drugs have limited efficacy. Stem cell therapy is now rec-
ognized as an alternative therapeutic tool for neurodegenera-
tive diseases for its potential in differentiation and paracrine 
secretions. The efficiencies of different MSC transplant modali-
ties and relevant mechanisms, however, are not yet clarified.
Behavioral therapeutic efficacy of pMSCs compared 
to AChE inhibitors
All rats showed improvement in the Morris water maze train-
Fig. 4. DAB staining (×20, objective lense) for STEM121 human cytoplasmic marker. DAB staining was performed for investigation of stem cell homing 
at the dentate gyrus region after pMSC administration. The pMSCs were found at the dentate gyrus region after both ICV and IV injections. No pM-
SCs were found in the control and lesion groups. Scale bar=100 μm. DAB, diaminobenzidine; pMSC, placenta-derived mesenchymal stem cell; ICV, 
intracerebroventricular; IV, intravenous.
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ing phase, indicating that all rats managed to adopt a certain st-
rategy for escaping the water. It was reported that rats with le-
sions of cholinergic pathways show poor acquisition of spatial 
memory and that they alternatively adopt a non-spatial search 
strategy.21 Our water maze results were in accordance with such 
findings; lesioned rats still showed similar improvement in 
training latency to the control rats. It is, therefore, highly likely 
that the lesioned rats used a random search strategy to find 
the platform rather than relying on learning and spatial cogni-
tive functions; this strategy is also apparent in the water maze 
probe test results in which the lesioned rats displayed signifi-
cantly poorer performance than the control rats in all three 
measurements (Fig. 2). This speculation is also consistent 
with former findings which showed that cholinergic dysfunc-
tion leads to downregulation of memory-related proteins, re-
sulting in cognitive impairment and memory loss.22 Also, in the 
probe test, ICV, IV, and donepezil group rats all recovered in 
performance compared to lesioned rats (except for the done-
pezil group in platform crossings), suggesting that pMSC ad-
ministration facilitated effects comparable to donepezil. Ad-
ditionally, we did not observe significant differences in terms 
of behavioral improvement between ICV and IV groups. Thus, 
we conclude that neither stem cell administration pathway is 
superior over the other in regard with the effect on cognitive 
behavior.
Molecular therapeutic efficacy of ICV and IV pMSC 
transplant modalities
Since the MS-hippocampus-mPFC memory circuit consists of 
a cholinergic system,12,21 we first assessed cholinergic neuro-
nal activities in the three regions of interest using an AChE as-
say. Injection of 192 IgG-saporin tended decrease AChE activ-
ity in the MS and led to a decline in AChE activities in the 
downstream hippocampus and mPFC regions as well (Fig. 3). 
Stem cell administration through ICV and IV routes resulted 
in no significant AChE activity increase from the lesion group 
in the MS region, but led to AChE functional recovery in the 
hippocampus (Fig. 3B). Since the dentate gyrus of the hippo-
Fig. 5. Immunofluorescence analysis of ChAT activity at the dentate gyrus region. Samples were stained with hNu, anti-ChAT, and DAPI (×20, objective 
lense). White arrows indicate cholinergic neurons and transplanted pMSCs in ChAT and hNu images, respectively. No co-localization was found be-
tween hNu and ChAT markers (white arrows), indicating that the injected pMSCs did not directly differentiate into cholinergic cells. Scale bar=40 μm. 
hNu, human anti-nuclei marker; ChAT, choline acetyltransferase; pMSC, placenta-derived mesenchymal stem cell.
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B
campus is a prime source of granule cell neurogenesis23 and 
the neighboring periventricular area also exhibits neural stem 
cells,24 the hippocampal region provides an adequate envi-
ronment for stem cell homing and neurogenesis. In effect, the 
injected pMSCs possibly migrated to the hippocampal region 
and helped restore cholinergic activity in the hippocampus, 
increasing cholinergic innervation to the mPFC and enhanc-
ing cholinergic activity at the mPFC as well. It is quite likely that 
the MS did not improve cholinergic activity due to its place-
ment upstream of the hippocampus in the circuit.
In order to verify whether the injected stem cells actually 
reached the hippocampal region, brain tissue sections of the 
rats in ICV and IV groups were stained using DAB immuno-
histochemistry for human cytoplasm. Stem cells were found 
localized in the hippocampus for both groups, mainly at the 
dentate gyrus (Fig. 4). Both IV and ICV administration of pM-
SCs into rodents allowed migration of the stem cells to the 
malfunctioning site of the brain parenchyma, which is consis-
tent with earlier findings.25-27 Although earlier studies found 
that most MSCs are filtered in the lungs, kidneys, spleen, and 
liver upon IV injection and only a small fraction of MSCs reach 
the brain target,28 our study showed that IV injection nonethe-
less resulted in some pMSC localization at the hippocampus 
and subsequent recovery in cognitive functions. Considering 
its minor invasiveness and easier administration, IV injection 
may also be relatively advantageous compared to ICV injec-
tion of pMSCs. However, in terms of cholinergic cell rescue, nei-
ther ICV nor IV injection method displayed significant domi-
nance over one another: both methods yielded similar results.
Neuroprotective effects of pMSC transplantation therapy
Our main question was how these transplanted stem cells 
helped restore cholinergic activity in the hippocampus. Our 
first hypothesis was that the injected pMSCs, once reaching 
the hippocampus, differentiated into cholinergic cells and re-
placed the lesions caused by injection of 192 IgG-saporin. 
However, ChAT immunostaining results showed no co-local-
ization between human nuclei and ChAT markers (Fig. 5), in-
dicating that this was not the case. Such results are also con-
sistent with earlier studies. MSC administration is thought to 
regulate Aβ accumulation not through direct differentiation 
but through interactions with local immune cells,29 and an in 
vitro experiment using a cellular model of AD showed that 
MSC and MSC secretome prolongs cell viability and promotes 
neuritogenesis, suggesting that MSC secretome has therapeu-
tic potentials for neurodegenerative diseases.30 The facts that a 
certain portion of our injected pMSCs reached the hippocam-
pus of the rats (Fig. 4), and that these pMSCs did not differen-
tiate into cholinergic neurons (Fig. 5), also suggest that there 
is a more complex therapeutic mechanism of injected pMSCs 
than mere differentiation.
Since many previous studies reported that immune reac-
tions are triggered by implanted MSCs in the brain,29,31 we in-
vestigated participants of immune reactions in the brain, mi-
croglia in our case, that may have influenced behavioral re-
habilitation of dementia model rats after MSC administration. 
As mentioned in the results, lesioned rats showed significantly 
increased numbers of microglial cells at the dentate gyrus of 
the hippocampus, and rats of both ICV and IV groups displayed 
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Fig. 6. Immunofluorescence analysis of the microglia at the dentate gyrus region using Iba1. (A) Samples were stained with Iba1 (green) and DAPI 
(blue) (×10, objective lense). The number of Iba1-positive microglial cells at the dentate gyrus significantly increased from the normal group to the le-
sion group. ICV and IV administrations of placenta-derived mesenchymal stem cell significantly reduced the number of microglial cells back to nor-
mal levels. Scale bar=200 μm. (B) The numbers of Iba1-positive microglial cells at the dentate gyrus region were counted for the four groups. Com-
parisons among groups were made using one-way analysis of variance followed by post hoc Fisher’s least significant difference method. *p<0.01, 
†p<0.001 for comparisons. ICV, intracerebroventricular; IV, intravenous.
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significantly reduced numbers of microglia compared to the 
lesioned rats and showed no significant difference from con-
trol rats (Fig. 6B). A limitation of study might be that normal 
rats were used as the control instead of sham-operated rats for 
experiments. However, statistical analysis of microglial cell 
counts revealed a similar trend between normal and sham-
operated rats, as shown in the results section.
Microglia are glial cells in the central nervous system that 
participate in innate immunity in response to pathology th-
rough numerous mechanisms, such as physical contact with 
and removal of injured neurons and their synapses,32 or even 
phagocytosis of whole neurons.33 This fundamental role of 
phagocytosis is essential for facilitation of neuronal circuit re-
organization, anti-inflammatory responses, and regeneration 
of new neurons.34 However, excessive phagocytosis activates 
production of toxic reactive oxygen species that can be detri-
mental to the surrounding neurons as well.35 The phagocytic 
activity of microglial cells can also lead to neuronal loss due to 
phagocytosis of live neurons and live neural precursor cells.36 
These results suggest that even though microglia carry out the 
beneficial function of clearing out damaged neuronal debris, 
excessively large numbers of microglial cells may not be desir-
able for normal neurons.
Therefore, our results showing that IV and ICV injections of 
pMSCs lower microglia count to normal levels imply that pM-
SCs serve a dual function of neural recovery and neuroprotec-
tion. Again, no significant difference in microglial counts was 
observed between IV and ICV groups, suggesting that neither 
method was superior over the other. Administration of pMSCs 
facilitated recovery of cognitive rehabilitation (Fig. 2) and cho-
linergic neuronal function in dementia model rats (Fig. 3), 
while keeping the number of microglial cells in check, protect-
ing functional neurons from unnecessary phagocytosis (Fig. 6). 
Although the mechanism by which these phenomena take pl-
ace remains as a subject for further research, it is possible that 
the injected pMSCs take over the neural repair roles of microg-
lia. Besides phagocytosis, microglia promotes generation of 
new neurons through secretion of signaling molecules such as 
brain-derived neurotrophic factor (BDNF).37-39 Also, although 
still under debate, some studies have reported that human 
MSC transplantation into rats leads to an increase in BDNF lev-
els at the injury site.40 Perhaps, similar paracrine effects of pM-
SCs facilitate the recovery of cholinergic neuronal systems, 
consequently leading to cognitive restoration of dementia 
model rats.
In summary, our results demonstrated that administration 
of pMSCs into dementia model rats facilitated recovery of 
cholinergic activity and cognitive function. This is supported 
by the results of the AChE assay and Morris water maze test. 
In addition, we found that both IV and ICV administrations of 
pMSCs were effective for targeted delivery of the stem cells 
into the hippocampus of the dementia model rats, and that 
neither injection method was significantly more effective than 
the other. As previously discussed, both ICV and IV routes 
have their advantages and drawbacks: ICV administration is 
highly target-specific but invasive, whereas IV injection is less 
invasive but is subject to filtration of pMSCs in various organs. 
Thus, both methods are reasonable candidates for stem cell 
administration, and the choice of method should be made 
under careful consideration of physiological conditions of the 
subject. Moreover, our results showed that the injected pM-
SCs did not directly differentiate into cholinergic neurons, but 
rather influenced generation of cholinergic neurons via some 
other mechanism. It is highly possible that microglia are one 
of the main factors involved in this process, and that pMSCs 
exert functions similar to microglial cells, such as secretion of 
trophic factors. Although further researches are necessary for 
clarification of the exact mechanisms involved and establish-
ment of optimal conditions for successful stem cell homing, 
the therapeutic effects of pMSCs, nonetheless, shed light on 
possible future clinical applications of stem cell therapy to de-
mentia and other neurodegenerative diseases.
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